[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Huang H, Dong X, Gao SL, Wu YL: Conservative resection for benign tumors of the proximal pancreas. World J Gastroenterol; 2009 Aug 28;15(32):4044-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative resection for benign tumors of the proximal pancreas.
  • AIM: To evaluate the safety and long-term prognosis of conservative resection (CR) for benign or borderline tumor of the proximal pancreas.
  • RESULTS: The indications were: serous cystadenomas in eight patients, insulinomas in six, non-functional islet cell tumors in three and solid pseudopapillary tumors in three.
  • CONCLUSION: CR is a safe and effective procedure for patients with benign tumors in the proximal pancreas, with careful CCI-PJ and postoperative MCCL.
  • [MeSH-major] Pancreas / surgery. Pancreatectomy / instrumentation. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticojejunostomy / instrumentation. Pancreaticojejunostomy / methods
  • [MeSH-minor] Adult. Aged. Cystadenoma, Serous / surgery. Female. Humans. Insulinoma / surgery. Islets of Langerhans / pathology. Islets of Langerhans / surgery. Male. Middle Aged. Pancreatic Fistula / surgery. Retrospective Studies. Surgical Procedures, Operative / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):179-85 [7817989.001]
  • [Cites] Diabet Med. 1998 Jul;15(7):539-53 [9686693.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):509-16; discussion 516-7 [10457309.001]
  • [Cites] Arch Surg. 2006 Mar;141(3):293-9 [16549696.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):804-12 [16769536.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1254-9 [17583892.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1704-11 [17929105.001]
  • [Cites] Br J Surg. 2008 Jan;95(1):85-91 [18041022.001]
  • [Cites] Pancreas. 2008 Jan;36(1):44-9 [18192880.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):434-8 [10759738.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):890-8 [10816633.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):711-6 [10873007.001]
  • [Cites] Br J Surg. 2000 Jul;87(7):883-9 [10931023.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(5):466-72 [11180872.001]
  • [Cites] Surgery. 2002 Nov;132(5):836-43 [12464868.001]
  • [Cites] Dig Surg. 2003;20(6):506-10 [14506331.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):532-8 [15239986.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):403-13 [1015887.001]
  • [Cites] Surgery. 1984 Oct;96(4):608-16 [6435270.001]
  • [Cites] Surgery. 1993 May;113(5):532-5 [8488471.001]
  • [Cites] Ann Surg. 1993 Sep;218(3):229-37; discussion 237-8 [8103982.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):545-52 [7952456.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • (PMID = 19705501.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2731956
  •  go-up   go-down


2. Hofer MD, Chang MC, Hirko KA, Rubin MA, Nosé V: Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Mod Pathol; 2009 Jul;22(7):933-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors.
  • The clinical follow-up data were examined and tumors were classified according to the 2004 World Health Organization criteria as benign behavior (WHO 1.1), uncertain behavior (WHO 1.2), well-differentiated endocrine carcinoma (WHO 2), and poorly differentiated endocrine carcinoma (WHO 3).
  • Metastasis-associated gene 1 expression was significantly higher in malignant tumors (n=17) with a mean staining intensity of 3.8 compared with 2.9 in benign tumors (n=10, P=0.046).
  • The expression levels were significantly associated with WHO class (P=0.028), as well as size of tumor (P=0.029), and mitotic rate (P=0.035).
  • [MeSH-major] Adenoma, Islet Cell / enzymology. Carcinoma, Islet Cell / enzymology. Histone Deacetylases / metabolism. Islets of Langerhans / enzymology. Pancreatic Neoplasms / enzymology. Repressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377441.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


3. Denève E, Ramos J, Aufort S, Marchand JP, Rousset T, Perrochia H, Domergue J, Navarro F: [Endocrine tumor arising in heterotopic gastric pancreas]. Gastroenterol Clin Biol; 2008 Feb;32(2):195-201
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine tumor arising in heterotopic gastric pancreas].
  • We report the case of a 49-year-old caucasian woman, in whom an endocrine tumor arising in gastric heterotopic pancreas was diagnosed.
  • Heterotopic pancreas is a benign anatomic condition, probably widely underdiagnosed because usually asymptomatic.
  • The malignant transformation of aberrant pancreas is very rare and almost always in adenocarcinoma.
  • The endocrine tumors developed in heterotopic pancreas are exceedingly rare.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Choristoma / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology. Stomach Diseases / pathology
  • [MeSH-minor] Carcinoma, Islet Cell / pathology. Female. Follow-Up Studies. Gastrins / analysis. Humans. Islets of Langerhans / pathology. Middle Aged. Somatostatin / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387430.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Gastrins; 51110-01-1 / Somatostatin
  •  go-up   go-down


Advertisement
4. Isidori AM, Lenzi A: Ectopic ACTH syndrome. Arq Bras Endocrinol Metabol; 2007 Nov;51(8):1217-25
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ectopic adrenocorticotropic secretion (EAS) is responsible for 12-17% of cases of Cushing's syndrome (CS) and covers a range of tumours, from undetectable benign lesions to widespread metastases.
  • EAS requires a complete workup that includes the establishment of endogenous CS, diagnosis of adrenocorticotropic hormone (ACTH) dependency, localization of the source of ACTH secretion and rapid biochemical control of hypercortisolaemia.
  • In addition to small cell lung carcinoma, the most common causes of ectopic EAS are bronchial carcinoids, thymic tumours, islet cell tumour of the pancreas, medullary thyroid carcinomas, and phaeochromocytomas.
  • [MeSH-major] ACTH Syndrome, Ectopic / diagnosis
  • [MeSH-minor] Abdominal Neoplasms / complications. Abdominal Neoplasms / secretion. Adrenocorticotropic Hormone / blood. Biomarkers / blood. Carcinoid Tumor / complications. Carcinoid Tumor / secretion. Corticotropin-Releasing Hormone. Cushing Syndrome / diagnosis. Diagnosis, Differential. Humans. Hydrocortisone / blood. Petrosal Sinus Sampling. Thoracic Neoplasms / complications. Thoracic Neoplasms / secretion. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209859.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 53
  •  go-up   go-down


5. Berrospi Espinoza F, Ruiz Figueroa E, Chavez Passiuri I, Celis Zapata J: [Laparoscopic treatment of insulinoma: surgical technique and perisurgical results]. Rev Gastroenterol Peru; 2005 Oct-Dec;25(4):366-70
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Four patients with clinical and radiological diagnosis of insulinoma were treated between January 2000 and September 2005.
  • RESULTS: All the patients were laparoscopically approached to attempt the tumor enucleation.
  • In three cases complete enucleation was possible; the remaining case was converted to perform the resection of the middle portion of the pancreas.
  • In all cases histological evaluation of the tumor showed benign islet cell tumor.

  • Genetic Alliance. consumer health - Insulinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16333393.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


6. Yang WB, Wang YH, Cai F, Cao G, Qin ZY: [Biological significance of expression of calcyclin in human pancreatic carcinoma: a tissue microarray-based study]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec;27(12):1908-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Human pancreatic carcinoma tissue microarray was constructed, which contained 63 cores of 3 normal adult pancreas tissues, 6 chronic pancreatitis tissues, 51 pancreatic carcinoma tissues and 3 islet cell carcinoma tissues.
  • RESULTS: The positivity rate of calcyclin in the pancreatic carcinoma tissue was 76.5% (39/51), and calcyclin staining was more intense in the malignant cells than in the benign cells (P=0.007), suggesting a correlation between calcyclin expression and pancreatic carcinoma.
  • No evidence was found for an association of calcyclin expression with the variables including the patients' gender, age at surgery, and tumor grade.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Pancreatic Neoplasms / metabolism. S100 Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Pancreatitis, Chronic / genetics. Pancreatitis, Chronic / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159017.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / S100 Proteins; 105504-00-5 / S100A6 protein, human
  •  go-up   go-down


7. Singh N, Lo CY, Chan WF: Laparoscopic enucleation of a nonfunctioning neuroendocrine tumor at the head of the pancreas. JSLS; 2006 Apr-Jun;10(2):259-62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic enucleation of a nonfunctioning neuroendocrine tumor at the head of the pancreas.
  • OBJECTIVE: Laparoscopy is a safe, feasible technique for benign pancreatic pathologies and has been increasingly reported for neuroendocrine tumors located at the body and tail of the pancreas.
  • We report a case of successful enucleation of a nonfunctioning neuroendocrine tumor located at the head of the pancreas, in a patient with multiple endocrine neoplasia type I.
  • METHODS: A 5-cm nonfunctioning neuroendocrine tumor at the pancreatic head was identified by computerized tomography scan.
  • Laparoscopic ultrasound did not reveal additional tumors on any other part of the pancreas.
  • RESULTS: Enucleation was successfully performed for this solitary tumor because of its favorable position.
  • Histology revealed an islet cell tumor.
  • CONCLUSION: Laparoscopic enucleation of neuroendocrine tumor at the pancreatic head is safe and feasible for select patients.

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jun;231(6):909-18 [10816635.001]
  • [Cites] Surgery. 2000 Sep;128(3):386-91 [10965308.001]
  • [Cites] Surgery. 2001 Dec;130(6):1086-91 [11742343.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1057-65 [12016486.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Eur J Endocrinol. 2003 Jan;148(1):39-43 [12534356.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):297-302 [14712388.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):488-93; discussion 493-4 [7725733.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] World J Surg. 2002 Oct;26(10):1297-300 [12205557.001]
  • (PMID = 16882434.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3016133
  •  go-up   go-down


8. Esposito I, Kayed H, Keleg S, Giese T, Sage EH, Schirmacher P, Friess H, Kleeff J: Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia; 2007 Jan;9(1):8-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.
  • Pancreatic ductal adenocarcinoma (PDAC) and other pancreatic neoplasms exhibited increased SPARCL1 mRNA levels compared to those of the normal pancreas.
  • SPARCL1 mRNA levels were low to absent in microdissected and cultured pancreatic cancer cells, and promoter demethylation increased SPARCL1 levels only slightly in three of eight cell lines.
  • SPARCL1 was observed in small capillaries in areas of inflammation/tumor growth and in some islet cells.
  • In contrast, the percentage of SPARCL1-positive vessels was higher in chronic pancreatitis and benign and borderline pancreatic tumors.
  • Recombinant SPARCL1 inhibited pancreatic cancer cell invasion and exerted moderate growth-inhibitory effects.
  • Its anti-invasive effects and reduced expression in metastasis indicate tumor-suppressor function.
  • [MeSH-major] Calcium-Binding Proteins / physiology. Extracellular Matrix Proteins / physiology. Pancreatic Neoplasms / prevention & control. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / prevention & control. Cell Line, Tumor. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / analysis. Transcription, Genetic

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1992 Jan 1;148(1):267-71 [1370171.001]
  • [Cites] Neuron. 1990 Jan;4(1):165-76 [1690015.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5289-96 [7693336.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3448-52 [8159767.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):95-100 [7856741.001]
  • [Cites] Immunity. 1995 Jan;2(1):113-23 [7600298.001]
  • [Cites] Int J Cancer. 1995 Feb 20;64(1):70-5 [7665251.001]
  • [Cites] J Biol Chem. 1996 Feb 23;271(8):4511-7 [8626806.001]
  • [Cites] Pancreas. 1996 Nov;13(4):395-400 [8899800.001]
  • [Cites] J Invest Dermatol. 1997 Feb;108(2):210-4 [9008236.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):232-6 [9443398.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):25-41 [9443985.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):626-9 [9485012.001]
  • [Cites] EMBO J. 1998 Apr 1;17(7):1860-70 [9524110.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1375-82 [9626453.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Dec;57(12):1112-21 [9862633.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):237-41 [10037170.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] J Pathol. 1999 Sep;189(1):46-52 [10451487.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4453-7 [10485497.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):923-33 [15743803.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):224-34 [16041213.001]
  • [Cites] Pancreas. 2006 Mar;32(2):119-29 [16552330.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):27621-32 [16844696.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1123-30 [10735494.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):521-6 [11179481.001]
  • [Cites] J Urol. 2001 Dec;166(6):2495-9 [11696817.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):91-9 [11786403.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):608-16 [12231357.001]
  • [Cites] J Clin Invest. 2003 Feb;111(4):487-95 [12588887.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):6045-50 [12721366.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5127-36 [14613990.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):991-6 [15094114.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):339-46 [15104296.001]
  • [Cites] Curr Med Res Opin. 2004 May;20(5):707-12 [15140337.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):668-76 [15146555.001]
  • [Cites] J Histochem Cytochem. 2004 Jun;52(6):735-48 [15150282.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):630-6 [15166270.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5338-46 [15289340.001]
  • [Cites] Biochemistry. 1988 Mar 8;27(5):1483-9 [2835093.001]
  • [Cites] Pancreas. 1988;3(2):180-8 [3131759.001]
  • [Cites] Genomics. 1988 Jan;2(1):37-47 [2838412.001]
  • [Cites] Curr Opin Immunol. 1992 Jun;4(3):277-86 [1418706.001]
  • (PMID = 17325739.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / SPARCL1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC1803032
  •  go-up   go-down


9. Xue HD, Liu W, Sun H, Merges R, Wang X, Zhang XN, Wang Y, Zhao WM, Chen JH, Jin ZY: Spectrum of functioning islet cell tumor on multislice computed tomography: experience on 70 patients. Chin Med Sci J; 2008 Mar;23(1):1-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of functioning islet cell tumor on multislice computed tomography: experience on 70 patients.
  • OBJECTIVE: To review experience in preoperative detection of islet cell tumors using multislice computed tomography (MSCT) and summarize various imaging features of functioning islet cell tumors on enhanced MSCT.
  • METHODS: Seventy patients with clinical or pathological diagnosis of functioning pancreatic islet cell tumor between October 2003 and February 2007 were included in this retrospective study.
  • Surgery and pathology reports were used to confirm the diagnosis, localization, and size of tumors.
  • RESULTS: Totally, 73 functioning islet cell tumors including 65 benign insulinomas, 2 benign glucagonomas, 3 malignant insulinomas, and 3 malignant glucagonomas were pathologically diagnosed.
  • In 67 benign lesions, 32 showed typical enhancement style, 21 showed prolonged enhancement in portal venous phase, 4 showed delayed enhancement, 4 had iso-dense enhancement with normal pancreatic parenchyma, 2 had no enhancement at all in arterial phase and portal venous phase, and 4 had inhomogeneous enhancement with necrosis or cyst-formation.
  • In 6 malignant islet cell tumors, vessel invasion (2/6) and bowel invasion (1/6) were seen.
  • CONCLUSIONS: Pancreatic islet cell tumor may display a wide spectrum of presentations in MSCT.
  • Non-contrast and post-contrast multiphase scans are recommended for the localization of functioning islet cell tumors.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437902.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Ikenaga N, Yamaguchi K, Konomi H, Fujii K, Sugitani A, Tanaka M: A minute nonfunctioning islet cell tumor demonstrating malignant features. J Hepatobiliary Pancreat Surg; 2005;12(1):84-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A minute nonfunctioning islet cell tumor demonstrating malignant features.
  • We report a patient with a minute nonfunctioning islet cell tumor, 8 mm in diameter, which demonstrated malignant features by histology.
  • Ultrasonography and computed tomography demonstrated a well-defined pancreatic tumor, 8 mm in diameter, in the body of the pancreas.
  • Serum levels of pancreatic hormones were within normal limits, and thus a tentative diagnosis was nonfunctioning islet cell tumor.
  • The size of the tumor remained unchanged for 1 1/2 years, but, at this time, the serum level of CA19-9 was elevated to 253 U/ml.
  • The resected specimen showed an endocrine tumor invading both the pancreatic parenchyma and the perineural spaces outside the tumor.
  • In general, minute nonfunctioning islet cell tumors have been considered to be completely benign, but the present tumor showed clear malignant features.
  • We might have to take surgical resection into consideration even if the size of such an endocrine tumor is minute.
  • [MeSH-major] Adenoma, Islet Cell / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Imaging. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754106.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Merritt JL 2nd, Davis DM, Pittelkow MR, Babovic-Vuksanovic D: Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations. Am J Med Genet A; 2006 Aug 1;140(15):1669-72
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations.
  • Acrochordons are frequently encountered benign skin lesions that may occasionally represent underlying pathology.
  • Pancreatic islet-cell tumors are rare neoplasms and few cases have been described in patients with tuberous sclerosis complex (TSC).
  • The diagnosis was confirmed by disclosure of mutation in the TSC2 gene.
  • Further evaluation revealed pancreatic islet cell tumors.
  • Additionally, mutations in TSC2 gene may be a risk factor for developing pancreatic islet-cell tumors.
  • [MeSH-major] Adenoma, Islet Cell / genetics. Adenoma, Islet Cell / pathology. Mutation. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. Skin Diseases / genetics. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Female. Humans. Male. Pedigree. Renal Insufficiency / diagnosis. Renal Insufficiency / genetics


12. Liang H, Wang XN, Wang BG, Pan Y, Ding XW, Hao XS: [Management of nonfunctioning islet cell tumors of the pancreas]. Zhonghua Zhong Liu Za Zhi; 2007 Jun;29(6):457-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of nonfunctioning islet cell tumors of the pancreas].
  • OBJECTIVE: To analyze the clinical and pathological features in order to investigate appropriate way of diagnosis and treatment for non-functional islet cell tumors of the pancreas (NFICT).
  • Twenty-eight patients were diagnosed as having non-functional islet cell carcinomas of the pancreas (NFICC) and 15 patients benign islet cell tumors.
  • Preoperatively, all of those were found to have a mass in their pancrease by ultrasonic and computed tomography examination, with 21 in the head, 10 in the body and 6 in the tail of the pancreas.
  • Multicemtric tumor were found in one patient.
  • The resectability and curative resection rate in 28 patients with nonfunctioning islet cell carcinomas of the pancreas was 78.6% and 60.7%, respectively.
  • None of the 15 patients with benign nonfunctioning islet cell tumor of the pancreas died of this disease.
  • While the overall cumulative 5- and 10-year survival rate in 28 patients with non-functional islet cell carcinomas of the pancreas was only 58.1% and 29.0%, respectively.
  • CONCLUSION: Nonfunctioning islet cell tumor of the pancreas is frequently found in young female.
  • [MeSH-major] Adenoma, Islet Cell / therapy. Carcinoma, Islet Cell / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974283.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


13. Sakata N, Egawa S, Motoi F, Mikami Y, Ishida M, Aoki T, Ottomo S, Fukuyama S, Rikiyama T, Katayose Y, Goto M, Unno M: Institutional indications for islet transplantation after total pancreatectomy. J Hepatobiliary Pancreat Surg; 2008;15(5):488-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Institutional indications for islet transplantation after total pancreatectomy.
  • BACKGROUND/PURPOSE: This study was designed to establish institutional indications for pancreatic islet transplantation by examining patients with total pancreatectomy as candidates for islet allotransplantation.
  • METHODS: In 12 patients who underwent total pancreatectomy, we compared pre-and postoperative plasma glucose level, body mass index, HbA1c, and daily insulin use; we examined candidacy for islet allotransplantation based on the guidelines of Japan's islet transplantation registry.
  • RESULTS: Eight of the 12 patients with total pancreatectomy were operated for intraductal papillary mucinous neoplasm.
  • At our institution, the 5-year survival of patients with intraductal papillary mucinous neoplasm was far better (76.3%) than that of patients with pancreatic cancer.
  • Of the 12 patients treated with total pancreatectomy, 4 (intraductal papillary mucinous neoplasm, n = 2; islet cell tumor, n = 1; and acute pancreatitis due to arteriovenous malformation, n = 1) showed deteriorated diabetic control and therefore were considered to be candidates for islet allotransplantation according to the guidelines.
  • CONCLUSIONS: Islet allotransplantation could be indicated for patients with favorable postoperative survival who have had a total pancreatectomy for either benign or neoplastic disease.
  • [MeSH-major] Diabetes Mellitus / surgery. Islets of Langerhans Transplantation. Pancreatectomy / adverse effects. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Islet Cell Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836802.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N: Role of medial pancreatectomy in the management of intraductal papillary mucinous neoplasms and islet cell tumors of the pancreatic neck and body. Dig Surg; 2008;25(1):46-51
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of medial pancreatectomy in the management of intraductal papillary mucinous neoplasms and islet cell tumors of the pancreatic neck and body.
  • BACKGROUND/AIM: Medial pancreatectomy has been applied as a safe and effective alternative in benign diseases located in the pancreatic neck or body.
  • Three patients with islet cell tumor and 1 patient with solid pseudopapillary tumor had no malignant disease.
  • CONCLUSIONS: A medial pancreatectomy is a safe and effective alternative for the treatment of intraductal papillary mucinous neoplasm, islet cell tumor, or solid pseudopapillary tumor located in the neck or body of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Adenoma, Islet Cell / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292661.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Zhou J, Dong M, Kong F, Li Y, Tian Y: Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases. J Surg Oncol; 2009 Sep 1;100(3):273-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases.
  • BACKGROUND: To discuss the advantage of central pancreatectomy in the patients with benign tumors of the neck and body of the pancreas.
  • RESULTS: Central pancreatectomy was done in eight patients including five mucinous cystadenomas, one serious cystadenoma, one insulinoma and one nonfunctional islet cell tumor.
  • CONCLUSION: Central pancreatectomy is a safe technique for benign tumors of the pancreatic neck and body, especially when the enucleation is very difficult.
  • [MeSH-minor] Adenoma, Islet Cell / surgery. Adult. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Female. Humans. Insulinoma / surgery. Male. Middle Aged. Pancreatic Fistula / etiology. Pancreatic Fistula / therapy. Postoperative Complications. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267362.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard CA, Buendia MA, Perret C: Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene; 2006 Jan 26;25(4):599-608
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.
  • We used PCR-based subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for beta-catenin.
  • They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Lithostathine / genetics. Liver Neoplasms / genetics. Mutation. beta Catenin / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Cell Line, Tumor. Colonic Neoplasms / genetics. Hepatoblastoma / genetics. Humans. Male. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314847.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / REG1A protein, human; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


17. Yang YS, Wang XD, Ji DG, Zhang D, Xie YJ, Meng ZH, Zhang XW: [Middle segment pancreatectomy for the benign tumors of the neck and body of the pancreas (report of 15 cases)]. Zhonghua Wai Ke Za Zhi; 2010 Sep 15;48(18):1402-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Middle segment pancreatectomy for the benign tumors of the neck and body of the pancreas (report of 15 cases)].
  • OBJECTIVE: To study the clinical application value of middle segment pancreatectomy in the treatment of benign tumors of the amphi-neck of the pancreas.
  • They all received middle segment pancreatectomy for benign tumors of the amphi-neck of the pancreas.
  • Postoperative pathology showed that in the 15 patients, 1 got solid-pseudopapillary tumor of the pancreas, 3 got non-functional islet cell tumor, 11 got cystadenoma of pancreas.
  • CONCLUSIONS: There is an exact therapeutic effect of middle segment pancreatectomy for benign tumors of the amphi-neck of the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092576.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Fasanella KE, McGrath KM, Sanders M, Brody D, Domsic R, Khalid A: Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality. Gastrointest Endosc; 2009 May;69(6):1074-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor EUS-guided FNA DNA microsatellite loss and mortality.
  • BACKGROUND: The clinical course of pancreatic endocrine tumors (PET) depends on tumor size, the presence of invasion or metastasis, the Ki-67 index, mitoses per high power field, and mutational damage.
  • Malignant PET contained multiple microsatellite losses, with a median fractional allelic loss (FAL) of 0.37 (range 0.12-0.69, interquartile range [IQR] 0.23-0.42), significantly different from benign PET, median FAL 0 (range 0-0.18, IQR 0-0.08, P < .0001).
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Islet Cell / genetics. Carcinoma, Islet Cell / ultrasonography. Endosonography. Loss of Heterozygosity / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / ultrasonography. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / genetics. Male. Middle Aged. Neoplasm Staging. Pancreas / pathology. Pancreas / ultrasonography. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2009 May;69(6):1081-4 [19410041.001]
  • (PMID = 19152901.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


19. de Boer J, Jager PL, Wiggers T, Nieboer P, Machteld Wymenga AN, Pras E, Hoogenberg K, Sleijfer DT, Suurmeijer AJ, van der Graaf WT: The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient. Int J Clin Oncol; 2006 Dec;11(6):478-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient.
  • We report a patient with a nonresectable histologically benign solitary fibrous tumor who suffered from paraneoplastic non-islet cell tumor hypoglycemia (NICTH).
  • Diagnostic workup revealed malignant characteristics in which the tumor showed up as, presumably, false-negative on fluorodeoxyglucose-positron emission tomography (FDG-PET), while being positive on tyrosine-PET.
  • Neoadjuvant treatment, which consisted of combined chemo-radiation and consecutive selective embolization of the tumor feeding vessels, caused such a therapeutic effect, on both NICTH and reduction in tumor volume, that a secondary resection, with the patient in a normoglycemic status, was possible.
  • Our report highlights several important issues in the management of the patient with a nonresectable solitary fibrous tumor with severe episodes of hypoglycemia due to NICTH.

  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180519.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


20. Hino N, Nakagawa Y, Ikushima Y, Yoshida M, Tsuyuguchi M: A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II. Breast Cancer; 2010 Apr;17(2):142-5
MedlinePlus Health Information. consumer health - Hypoglycemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a giant phyllodes tumor of the breast with hypoglycemia caused by high-molecular-weight insulin-like growth factor II.
  • Because we suspected that the big IGF-II was produced by the breast tumor and was likely the cause of the hypoglycemia, a mastectomy was performed.
  • A histological examination determined that the mass was a benign phyllodes tumor.
  • We suspected that the patient had non-islet cell tumor hypoglycemia (NICTH), but the behavioral symptoms of the hypoglycemia caused by NICTH were similar to some mental diseases, which made diagnosis based on the behavior alone difficult.
  • We suggest that co-occurrence of symptoms such as recent appearance of mental disease-like behavior, hypoglycemia, and giant breast tumor may help diagnose NICTH caused by big IGF-II.
  • [MeSH-major] Breast Neoplasms / etiology. Hypoglycemia / etiology. Insulin-Like Growth Factor II / metabolism. Phyllodes Tumor / etiology


21. Kapran Y, Bauersfeld J, Anlauf M, Sipos B, Klöppel G: Multihormonality and entrapment of islets in pancreatic endocrine tumors. Virchows Arch; 2006 Apr;448(4):394-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Classified according to the WHO classification, there were 32 well-differentiated benign PETs, 85 well-differentiated PETs with uncertain behavior, and 83 well-differentiated malignant PETs.
  • Islet entrapment was found in 57 tumors (28.5%) and was significantly more frequent in PETs with uncertain and malignant behavior than benign ones (p=0.01).
  • In 57 cases, we also investigated whether ductule entrapment accompanied islet entrapment.
  • We conclude that the incidence of multihormonality in PETs is not as high as suggested previously and islet entrapping may reflect aggressive tumor growth and may be a complementary criterion for predicting the biological behavior of PETs.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Islets of Langerhans / pathology. Pancreatic Hormones / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Count. Child. Child, Preschool. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418841.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pancreatic Hormones
  •  go-up   go-down


22. Hu MG, Zhao GD, Luo Y, Liu R: [Clinical applications of laparoscopic pancreatectomy]. Zhonghua Yi Xue Za Zhi; 2010 Jul 27;90(28):1948-51
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The preoperative diagnoses included insulinoma (n = 38), cystadenoma (n = 4), cystadenocarcinoma (n = 1), nonfunctional islet cell tumor (n = 5) and solid-pseudopapillary tumor (n = 1).
  • CONCLUSION: Laparoscopic pancreatectomy is safe and feasible in the treatment of most benign pancreatic diseases and some malignant tumors.
  • [MeSH-major] Adenoma, Islet Cell / surgery. Laparoscopy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979855.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Shah OJ, Robbani I, Nazir P, Khan AB: Central pancreatectomy: a new technique for resection of selected pancreatic tumors. Hepatobiliary Pancreat Dis Int; 2009 Feb;8(1):93-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For small benign tumors enucleation is not usually feasible due to their size and localization; then pancreatectomy is often needed.
  • Central pancreatectomy consists of a limited resection of the midportion of the pancreas and can be offered in benign and low-grade malignant tumors of the neck of the pancreas.
  • RESULTS: Four patients, two with serous cystadenoma, and one with an islet cell tumor, and one with a hydatid cyst, were identified for the procedure.
  • The mean tumor size was 3 cm, the mean operative time was 217.5 minutes, and the mean blood loss was 382.5 ml.
  • CONCLUSIONS: Central pancreatectomy is a procedure that offers excellent results in benign and low-grade malignant tumors.
  • It preserves functional elements (endocrine and exocrine) of the pancreas and also eliminates the infective and hematological effects of splenectomy.
  • [MeSH-major] Cystadenoma / surgery. Echinococcosis / surgery. Pancreas / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / pathology. Adenoma, Islet Cell / surgery. Adult. Biopsy. Female. Follow-Up Studies. Humans. Male. Postoperative Complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208523.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Long KB, Srivastava A, Hirsch MS, Hornick JL: PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol; 2010 May;34(5):723-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PAX (paired box) genes encode a family of transcription factors that regulate organogenesis and cell-lineage specification in multiple organ systems.
  • In the pancreas, PAX proteins play a critical role in islet cell differentiation.
  • We recently observed that islet cells show strong, diffuse staining for PAX8 by immunohistochemistry.
  • Expression of PAX8 was significantly associated with WHO category 1.1 ("benign" behavior) compared with category 1.2 (uncertain behavior) or 2 (well-differentiated endocrine carcinoma) (positive in 100%, 64%, and 52% of tumors, respectively; P<0.05).
  • In summary, PAX8 is expressed in normal pancreatic islet cells and in a high proportion of primary and metastatic PETs.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoid Tumor / pathology. Carcinoma, Islet Cell / secondary. Gastrointestinal Neoplasms / pathology. Lung Neoplasms / pathology. Paired Box Transcription Factors / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Dec;35(12):1906-8 [22067332.001]
  • (PMID = 20414099.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


25. Fernández-Cruz L, Blanco L, Cosa R, Rendón H: Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg; 2008 May;32(5):904-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the first reports with laparoscopic resection of islet cell tumors in 1996, the experience worldwide is still limited, with only short-term outcomes available.
  • Some have suggested that a malignant tumor is a contraindication to laparoscopic resection.
  • Aim The aim of this study was to evaluate the feasibility, safety, and long-term outcome of the laparoscopic approach in patients with functioning, nonfunctioning, or overt malignant pancreatic neuroendocrine tumor (PNT).
  • Other than 9 PNTs localized in the head of the pancreas, all tumors were located in the left pancreas.
  • Sixteen patients had a nonfunctioning tumor (mean size 5 cm).
  • Long-term outcomes were analyzed by tumor recurrence and patient survival.
  • Conclusions This series demonstrates that LPS is feasible and safe in benign-appearing and malignant neuroendocrine pancreatic tumors (NEPTs).
  • The benefits of minimally invasive surgery were manifest in the short hospital stay and acceptable pancreas-related complications in high-risk patients.
  • [MeSH-major] Carcinoma, Islet Cell / surgery. Laparoscopy. Neuroendocrine Tumors / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264824.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Tomita T: Cleaved caspase-3 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors: A potential marker for biological malignancy. Islets; 2010 Mar-Apr;2(2):82-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Control islets revealed some CC-3 positive cells, ranging from 3.6 to 7.3% of total islet cells.
  • Small islets in the pseudocapsule of PETs showed higher immunopositive cells at about 9% for CC -3, suggesting an accelerated apoptosis in these compressed, elongated islets before proceeding to imminent cell death.
  • Since 21 of 24 (88%) of potentially malignant primary non-β-cell PETs were negative, whereas 5 of 12 (42%) benign insulinomas were positive for CC-3 immunostaining, CC-3 negative immunostaining may serve as a possible malignant marker for all PETs.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Caspase 3 / metabolism. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Diagnostic Techniques, Endocrine. Female. Humans. Immunohistochemistry / methods. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Male. Middle Aged. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / metabolism. Neuroendocrine Tumors / pathology. Protein Processing, Post-Translational / physiology. Rabbits. Staining and Labeling / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099299.001).
  • [ISSN] 1938-2022
  • [Journal-full-title] Islets
  • [ISO-abbreviation] Islets
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 3; Pancreatic islet cell tumors
  •  go-up   go-down


27. Christein JD, Smoot RL, Farnell MB: Central pancreatectomy: a technique for the resection of pancreatic neck lesions. Arch Surg; 2006 Mar;141(3):293-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although historically used for traumatic pancreatic transection and chronic pancreatitis, it currently is reserved for selective management of pancreatic neck lesions that are benign or have low malignant potential.
  • Our objectives were to describe the technique and determine the safety and effectiveness of central pancreatectomy in the excision of benign or low-malignant potential lesions of the pancreatic neck.
  • RESULTS: Abnormalities included 3 islet cell tumors, 2 serous cystadenomas, a mucinous cystadenoma, a lymphoepithelial cyst, and a recurrent liposarcoma.
  • Mean tumor size was 2.8 cm and mean operative time was 4.8 hours with a mean blood loss of 381 mL.
  • The precise role of central pancreatectomy in the management of benign or low-malignant potential lesions of the neck of the pancreas remains in evolution.
  • [MeSH-minor] Adenoma, Islet Cell / radiography. Adenoma, Islet Cell / surgery. Cystadenoma, Serous / radiography. Cystadenoma, Serous / surgery. Female. Humans. Liposarcoma / surgery. Male. Mesenteric Veins / surgery. Middle Aged. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549696.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol; 2008 Jan;129(1):81-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.
  • We immunohistochemically evaluated the diagnostic value of S100P on cell-block and/or smear preparations in 58 cases of FNAB specimens of the pancreas.
  • The 58 cases were divided into 4 groups: 1, 32 cases of PDA; 2, 6 cases with an atypical or "suspicious" diagnosis; 3, 14 cases of benign or reactive ductal epithelium; and 4, 6 cases of endocrine tumor.
  • S100P is a sensitive and specific marker for the detection of PDA on FNAB specimens on cell-block and smear preparations.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carrier Proteins / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Biopsy, Fine-Needle. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089492.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / S100PBP protein, human
  •  go-up   go-down


29. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


30. Willmore-Payne C, Volmar KE, Huening MA, Holden JA, Layfield LJ: Molecular diagnostic testing as an adjunct to morphologic evaluation of pancreatic ductal system brushings: potential augmentation for diagnostic sensitivity. Diagn Cytopathol; 2007 Apr;35(4):218-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our series included twelve adenocarcinomas, one islet cell tumor, one case of dysplasia, and six benign cases.
  • No mutations were detected in benign lesions or in the dysplasia.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / genetics. Molecular Diagnostic Techniques. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / genetics
  • [MeSH-minor] DNA Mutational Analysis. Genes, ras / genetics. Humans. Immunohistochemistry. Mutation. Polymerase Chain Reaction. Proto-Oncogene Proteins B-raf / genetics. Receptor, Epidermal Growth Factor / genetics. Sensitivity and Specificity. Tumor Suppressor Protein p53 / genetics


31. Evert M, Schildhaus HU, Schneider-Stock R, Dombrowski F: Cystic cholangiomas after transplantation of pancreatic islets into the livers of diabetic rats. Virchows Arch; 2006 Jun;448(6):776-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Islet transplantation is increasingly used as a therapy for human type 1 diabetes mellitus.
  • A few days after low-number islet transplantation, cholangiocytes adjacent to the grafts showed an increase in proliferative activity.
  • During the next 12-24 months, many peri-insular ductules progressed via tumor-like cystic lesions to large cystic cholangiomas, accompanied by a translocation of the insulin receptor into the cytoplasm and an increase in expression of insulin-related signaling proteins (Insulin-receptor-substrate-1, Raf-1, Mek-1).
  • After 24 months, 53% of rats with low-number transplantation exhibited at least one cholangioma >10 mm, significantly outnumbering tumor development in the transplant-free left liver part and in any control group.
  • A graft cell origin of the tumors was excluded by Y chromosome in situ hybridization in cross-gender transplantations.
  • Conclusively, low-number intrahepatic islet transplantation, most likely acting by permanent local hyperinsulinism, leads to prolonged cholangiocellular proliferation in streptozotocin- and in autoimmune-diabetic rats, resulting in the development of benign cystic cholangiomas.
  • [MeSH-major] Adenoma, Bile Duct / etiology. Bile Duct Neoplasms / etiology. Bile Ducts, Intrahepatic / pathology. Diabetes Mellitus, Experimental / complications. Diabetes Mellitus, Type 1 / complications. Islets of Langerhans Transplantation / adverse effects
  • [MeSH-minor] Animals. Blood Glucose / analysis. Body Weight. Cell Proliferation. Female. Fluorescent Antibody Technique, Indirect. Immunoenzyme Techniques. Liver / pathology. Liver / surgery. Male. Rats. Rats, Inbred BB. Rats, Inbred Lew


32. Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg; 2006 Aug;141(8):765-9; discussion 769-70
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: Neuroendocrine tumors of the pancreas can be managed surgically with excellent outcomes.
  • Thirty-seven patients (52.9%) had neuroendocrine carcinomas and 13 (18.6%) had benign islet cell neoplasms.
  • Patients undergoing enucleation as compared with those not undergoing enucleation were younger (mean age, 39 vs 51 years, respectively; P = .009) and had smaller tumors (mean tumor size, 2 vs 5 cm, respectively; P<.001).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924083.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Lee CJ, Scheiman J, Anderson MA, Hines OJ, Reber HA, Farrell J, Kochman ML, Foley PJ, Drebin J, Oh YS, Ginsberg G, Ahmad N, Merchant NB, Isbell J, Parikh AA, Stokes JB, Bauer T, Adams RB, Simeone DM: Risk of malignancy in resected cystic tumors of the pancreas &lt; or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg; 2008 Feb;12(2):234-42
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of malignancy in resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report.
  • Among the 166 pancreatic resections for cystic pancreatic tumors < or =3 cm, 135 cases were benign [38 serous cystadenomas, 35 mucinous cystic neoplasms, 60 intraductal papillary mucinous neoplasms (IPMN), 1 cystic papillary tumor, and 1 cystic islet cell tumor], whereas 31 cases were malignant (14 mucinous cystic adenocarcinomas and 13 invasive carcinomas and 4 in situ carcinomas arising in the setting of IPMN).
  • Older age was associated with malignancy (mean age 67 years in patients with malignant disease vs 62 years in patients with benign lesions (p < 0.05).
  • All but three (6.6%) of the patients in this group had benign disease.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040749.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


34. Paik WH, Yoon YB, Lee SH, Park JK, Woo SM, Yang KY, Seo JK, Ryu JK, Kim YT: [Pancreatic endocrine tumors: clinical manifestations and predictive factors associated with survival]. Korean J Gastroenterol; 2008 Sep;52(3):171-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to recent advances in CT/MRI technology, incidentalomas of the pancreas are detected with increasing frequency.
  • Overall 5-year survival rate was 68.1%, and 5-year survival rate of the patients who had distant metastases at initial diagnosis was 43.9%.
  • However, tumor size and pathology showed no significant association with survival.
  • CONCLUSIONS: Because small and pathologically benign nature do not predict good prognosis in PET, aggressive treatment such as curative resection would be considered initially even in the case of incidental PET.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / mortality. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077513.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


35. Ketari-Jamoussi S, Debbiche-Chedly A, Ben Dhaou B, Boussema F, Cherif O, Cherif AR, Ben Ayed M, Bouzaine A, Rokbani L: [Giant insulinoma]. Ann Endocrinol (Paris); 2009 Mar;70(1):71-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Islet-cell tumors are the most common neuroendocrine tumors that arise from the endocrine pancreas.
  • They are typically benign and sporadic.
  • Diagnosis is generally established late because clinical signs lack specificity.
  • Imaging studies showed a voluminous tumor located between the pancreas and the spleen.
  • Histopathological examination revealed a malignant, well-differentiated neuroendocrine malignant tumor.

  • Genetic Alliance. consumer health - Insulinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937931.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 9035-68-1 / Proinsulin
  •  go-up   go-down


36. Muscarella LA, Barbano R, Augello B, Formica V, Micale L, Zelante L, D'Agruma L, Merla G: An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocytoma. J Hum Genet; 2007;52(6):485-91
Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system hemangioblastomas are benign vascular tumours that may present sporadically or as manifestation of the von Hippel-Lindau (VHL) disease.
  • VHL Syndrome is a rare autosomal dominant disorder characterized, besides hemangioblastomas, by susceptibility to multifocal and bilateral renal cell carcinoma and cysts, retinal angiomas, pheochromocytoma, epididymis cystoadenoma, pancreatic cysts and/or islet cell tumours.
  • Germline mutations of VHL tumour suppressor gene cause the VHL disease, while somatic mutations have been associated with sporadic hemangioblastomas and clear-cell renal carcinomas.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Cerebellar Neoplasms / genetics. Hemangioblastoma / genetics. Kidney Neoplasms / genetics. Promoter Regions, Genetic. Von Hippel-Lindau Tumor Suppressor Protein / genetics. von Hippel-Lindau Disease / genetics


37. Menéndez-Skertchly AL, Ortiz-Hidalgo C, Quijano-Orvańanos F, Cervantes-Monteil F, Chousleb-Kalach A, Padilla-Longoria R, Godoy-Valdés S, Vidal-González P, Herrera MF: [Endocrine tumors of the pancreas: experience in the ABC Medical Center]. Rev Gastroenterol Mex; 2006 Jul-Sep;71(3):296-301
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine tumors of the pancreas: experience in the ABC Medical Center].
  • OBJECTIVES: To analyze presentation, diagnosis and treatment of islet cell tumors at the ABC Medical Center.
  • The tumor was localized before surgery in 2 cases.
  • In all patients intraoperative ultrasound confirmed the tumor and enucleation was performed in all three.
  • A tumor in the pancreatic head was found and it was resected by pancreaticoduodenectomy.
  • Both non functioning tumors were found by imaging studies, one benign tumor was treated by central pancreatectomy and the other was malignant and underwent distal en-block pancreatectomy.
  • Immunohistochemistry was positive for VIP in the benign lesion.
  • CONCLUSIONS: Distribution of islet cell tumors in our series followed the usual patterns.
  • Imaging studies localized the tumor in 7 of the 8 patients.
  • Surgical resection cured all benign tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140051.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


38. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P: The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol; 2005 Mar;31(2):164-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
  • AIM: Serum tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA242 were investigated to evaluate the values of single and combined test in the diagnosis and prognosis of pancreatic cancer.
  • METHODS: Pre-operative serum CEA, CA19-9 and CA242 were measured in 105 pancreatic cancers, 70 non-pancreatic malignancies and 30 benign pancreatic diseases.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Islet Cell / blood. Carcinoma, Islet Cell / diagnosis. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater / metabolism. Ampulla of Vater / pathology. Bile Duct Neoplasms / blood. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Bilirubin / blood. Cholangiocarcinoma / blood. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Sensitivity and Specificity. Statistics as Topic. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698733.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA 242 antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


39. Inan N, Arslan A, Akansel G, Okay E, Gurbuz Y: Unusual magnetic resonance image of an insulinoma with extensive desmoplastic reaction. JOP; 2008;9(1):61-6
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Unlike other islet-cell tumors, insulinomas are usually benign.
  • Delayed contrast enhancement reflects the desmoplastic component of this tumor.

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182746.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 9007-34-5 / Collagen; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


40. Namasivayam S, Martin DR, Saini S: Imaging of liver metastases: MRI. Cancer Imaging; 2007;7:2-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific characterization of liver metastases in patients with primary non-hepatic tumors is crucial to avoid unnecessary diagnostic work-up for incidental benign liver lesions.
  • MR contrast agents provide critical tumor characterization and can be safely used in patients with iodine contrast allergy and renal failure.
  • The degree and nature of tumor vascularity form the basis for liver lesion characterization based on enhancement properties.
  • Neuroendocrine tumors including carcinoid and islet cell tumors, renal cell carcinoma, breast, melanoma, and thyroid carcinoma are tumors most commonly causing hypervascular hepatic metastases, which may develop early enhancement with variable degrees of washout and peripheral rim enhancement.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1407-13 [7484575.001]
  • [Cites] Radiology. 1995 Aug;196(2):471-8 [7617863.001]
  • [Cites] Radiology. 1996 Mar;198(3):881-7 [8628887.001]
  • [Cites] Radiology. 1996 May;199(2):513-20 [8668804.001]
  • [Cites] Radiology. 1996 Jul;200(1):59-67 [8657946.001]
  • [Cites] Radiology. 1996 Sep;200(3):785-92 [8756932.001]
  • [Cites] J Magn Reson Imaging. 1996 Mar-Apr;6(2):291-4 [9132092.001]
  • [Cites] Eur Radiol. 1997;7(2):275-80 [9038130.001]
  • [Cites] Radiology. 1997 May;203(2):449-56 [9114103.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):626-30 [9245955.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):631-7 [9245956.001]
  • [Cites] Radiol Clin North Am. 1998 Mar;36(2):287-97 [9520982.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2005 May;13(2):241-54, v-vi [15935310.001]
  • [Cites] Radiol Clin North Am. 2005 Sep;43(5):861-86, viii [16098344.001]
  • [Cites] Cancer Imaging. 2005;5 Spec No A:S149-56 [16361131.001]
  • [Cites] AJR Am J Roentgenol. 2006 Apr;186(4):1051-8 [16554578.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1337-45 [16453115.001]
  • [Cites] Cancer Imaging. 2006;6:33-42 [16766267.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1898-905 [16691378.001]
  • [Cites] Radiology. 1999 Oct;213(1):86-91 [10540645.001]
  • [Cites] Radiology. 2000 Apr;215(1):89-94 [10751472.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2000 Nov;8(4):741-56 [11149677.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):73-90 [11933597.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):165-79, vii [11933587.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jul;151(1):79-84 [3259825.001]
  • [Cites] Radiology. 1992 Jan;182(1):167-74 [1309218.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jan-Feb;17(1):67-74 [8419443.001]
  • [Cites] Radiology. 1994 Dec;193(3):657-63 [7972804.001]
  • [Cites] Radiology. 1995 Dec;197(3):575-7 [7480718.001]
  • (PMID = 17293303.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC1804118
  •  go-up   go-down


41. Morana G, Guarise A: Cystic tumors of the pancreas. Cancer Imaging; 2006;6:60-71
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic tumors of the pancreas.
  • Cystic tumors of the pancreas are less frequent than solid lesions and are often detected incidentally, as many of these lesions are small and asymptomatic.
  • With advancements in diagnostic imaging, cystic lesions of the pancreas are being detected with increasing frequency.
  • Many lesions can cause a pancreatic cyst, most being non-neoplastic while approximately 10% are cystic tumors, ranging from benign to highly malignant tumors.
  • With increasing experience it is becoming clear that the prevalence of pseudocyst among cystic lesions of the pancreas is lower than usually presumed.
  • A presumptive diagnosis of pseudocyst based on imaging appearance alone can cause a diagnostic error, and neoplastic cysts of the pancreas are particularly susceptible to this misdiagnosis, which can result in inappropriate treatment.
  • Cystic tumors of the pancreas are formed by serous or mucinous structures showing all stages of cellular differentiation.
  • According to the WHO classification, they can be subdivided on the basis of their histological type and biological behavior into benign tumors, borderline tumors, and malignant tumors.
  • Cystic pancreatic tumors can be subdivided into peripheral (serous cystadenomas, mucinous cystic tumors, solid and papillary epithelial neoplasms, cystic islet cell tumors), which do not communicate with the main pancreatic duct, and ductal tumors (mucinous tumor), according to their site of origin.
  • [MeSH-major] Cystadenoma / diagnosis. Diagnostic Imaging. Pancreatic Neoplasms / diagnosis. Pancreatic Pseudocyst / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Radiographics. 1999 Nov-Dec;19(6):1447-63 [10555668.001]
  • [Cites] J Comput Assist Tomogr. 1999 Nov-Dec;23(6):906-12 [10589565.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):441-7 [10658722.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):7-15 [10721803.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1403-8 [10789803.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):99-103 [10882255.001]
  • [Cites] Acta Radiol. 2000 Jul;41(4):343-7 [10937755.001]
  • [Cites] Ann Chir. 2000 Jul;125(6):571-7 [10986770.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Surgery. 2001 Jan;129(1):55-65 [11150034.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):323-37; discussion 337-40 [11259696.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Dig Dis. 2001;19(1):57-62 [11385252.001]
  • [Cites] Eur Radiol. 2001;11(9):1626-30 [11511881.001]
  • [Cites] Eur Radiol. 2001;11(10):1939-51 [11702126.001]
  • [Cites] Abdom Imaging. 2001 Nov-Dec;26(6):640-7 [11907731.001]
  • [Cites] Radiology. 2002 May;223(2):547-53 [11997566.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Oct;12(4):673-96 [12607779.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] ANZ J Surg. 2003 Jun;73(6):410-5 [12801340.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):185-207 [15238892.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(2):171-83 [7281507.001]
  • [Cites] Radiology. 1987 Oct;165(1):51-5 [3306789.001]
  • [Cites] Hepatogastroenterology. 1989 Dec;36(6):462-6 [2613167.001]
  • [Cites] Gastrointest Endosc. 1990 Jul-Aug;36(4):410-1 [2210291.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Gastrointest Radiol. 1991 Winter;16(1):53-61 [1991611.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):199-201 [1851710.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):465-71 [2065922.001]
  • [Cites] Am J Gastroenterol. 1992 May;87(5):634-8 [1317671.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Am Surg. 1993 Nov;59(11):740-5 [7694532.001]
  • [Cites] Curr Probl Surg. 1994 Mar;31(3):165-243 [8168359.001]
  • [Cites] J Comput Assist Tomogr. 1994 May-Jun;18(3):420-6 [8188910.001]
  • [Cites] Radiology. 1996 Jun;199(3):707-11 [8637992.001]
  • [Cites] Int J Pancreatol. 1995 Dec;18(3):197-206 [8708390.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):714-20 [8799419.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):967-70 [8884322.001]
  • [Cites] Am J Gastroenterol. 1996 Dec;91(12):2548-54 [8946984.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] Int J Pancreatol. 1996 Oct;20(2):135-9 [8968870.001]
  • [Cites] Presse Med. 1996 Nov 23;25(36):1794-800 [8991029.001]
  • [Cites] J Comput Assist Tomogr. 1997 May-Jun;21(3):373-82 [9135643.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):887-90 [9149208.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):637-44; discussion 644-6 [9230804.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Radiographics. 1998 Mar-Apr;18(2):433-49 [9536488.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Radiology. 1998 Jul;208(1):231-7 [9646818.001]
  • [Cites] Abdom Imaging. 1996 May-Jun;21(3):554-8 [9734981.001]
  • [Cites] Scand J Gastroenterol. 1998 Aug;33(8):880-9 [9754738.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):467-70 [9931400.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1973-80 [9951850.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1981-5 [9951851.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):483-91 [10228848.001]
  • [Cites] Int J Pancreatol. 1999 Apr;25(2):123-33 [10360225.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jun;29(6):294-8 [10418558.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • (PMID = 16861136.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1693784
  •  go-up   go-down


42. Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M: An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg; 2006 Dec;244(6):845-51; discussion 852-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of PETs was based on clinical symptoms, biochemical tests, and histopathology.
  • RESULTS: A total of 33 patients with a median age of 42 years were identified for this study: 13 patients had gastrinomas, 12 patients had nonfunctional islet cell tumors, 6 patients had insulinomas, and 2 patients had vipomas; 24 patients had sporadic NETs, 9 patients had a MEN-1-syndrome; 27 patients had histologically verified malignant tumors; 33 initial operations and 50 reoperations were performed.
  • The initial procedures comprised 27 resections of the primary tumor and 6 explorative laparotomies; 28 of all reoperations were resections of distant metastases, including 15 liver resections; 19 resections of the pancreas or duodenum were performed during reoperations.
  • All 6 patients with benign tumors are still alive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Nov;24(11):1418-24 [11038216.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Cancer Control. 2002 Jan-Feb;9(1):67-79 [11907468.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):855-62 [12417506.001]
  • [Cites] Surgery. 2002 Dec;132(6):976-82; discussion 982-3 [12490844.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):29-37 [12831921.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):859-66 [12912744.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Apr 23;129(17):941-6 [15083396.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):757-73 [15492556.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] Surgery. 1988 Dec;104(6):1011-7 [2904180.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):393-8; discussion 398-9 [1973323.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Aug;73(2):281-7 [1677362.001]
  • [Cites] Arch Surg. 1993 Jun;128(6):683-90 [8099273.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):320-8; discussion 328-30 [7916560.001]
  • [Cites] World J Surg. 1998 Jun;22(6):581-6; discussion 586-7 [9597932.001]
  • [Cites] World J Surg. 1998 Jul;22(7):666-71; discussion 671-2 [9606279.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):495-500 [9681848.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):286-93 [9922308.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):615-30 [10080607.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1353-60 [11038206.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):36-42; discussion 42-3 [7817996.001]
  • [Cites] World J Surg. 1996 Sep;20(7):908-14; discussion 914-5 [8678970.001]
  • [Cites] Surgery. 1996 Dec;120(6):1055-62; discussion 1062-3 [8957495.001]
  • [Cites] Gut. 2005 Feb;54(2):289-96 [15647196.001]
  • [Cites] Surgery. 2004 Dec;136(6):1205-11 [15657577.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):170-85 [15719379.001]
  • [Cites] Chirurg. 2005 Mar;76(3):217-26 [15688179.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):577-83 [16183528.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):699-704 [16253894.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81 [16253899.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):783-98 [16253900.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):819-30 [16253903.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):757-64, discussion 764-6 [16327485.001]
  • [Cites] Surgery. 2001 Feb;129(2):170-5 [11174710.001]
  • (PMID = 17122609.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1856628
  •  go-up   go-down






Advertisement